Other
CN
EU
USA
Description: Dorsomorphin (BML-275) is a reversible and selective AMPK (AMP-activated protein kinase) inhibitor with a Ki of 109 nM in cell-free assays, exhibiting little effects against closely related kinases such as ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin is also an inhibitor of BMP signaling, which promotes cardiomyogenesis in embryonic stem cells. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling.
References: Nat Chem Biol. 2008 Jan;4(1):33-41; J Biol Chem. 2006 Nov 17;281(46):34870-9.
Related CAS #: 866405-64-3 (free base); 1219168-18-9 (HCl)
Product Catalog 2022
Guide to Product Handling
Molecular Weight (MW)
399.49
Formula
C24H25N5O
CAS No.
866405-64-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 3 mg/mL (7.5 mM)
Water: <1 mg/mL
Ethanol: 2 mg/mL (5.0 mM)
Other info
Chemical Name: 6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine
InChi Key: XHBVYDAKJHETMP-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2
SMILES Code: C12=C(C3=CC=NC=C3)C=NN1C=C(C4=CC=C(OCCN5CCCCC5)C=C4)C=N2
Synonyms
BML-275,Compound C; BML275; BML-275; BML 275; CpdC; Dorsomorphin
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In Vitro
In vitro activity: Dorsomorphin inhibits ACC inactivation by either AICAR or metformin, and also attenuates AICAR and metformin’s effect to increase fatty acid oxidation or suppress lipogenic genes in hepatocytes.Inhibition of AMPK activity by Dorsomorphin almost completely inhibits autophagic proteolysis in HT-29 cells. in addition, Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6, and thus blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription and osteogenic differentiation.
Kinase Assay: Dorsomorphin dihydrochloride (BML-275 dihydrochloride; Compound C dihydrochloride) is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6.
Cell Assay: Dorsomorphin (compound C) (0-10 μM, 18 h) suppresses 2DG-induced GRP78 promoter activity in human fibrosarcoma HT1080 cells in a dose-dependent manner but has little effect on tunicamycin-induced GRP78 promoter activity. Dorsomorphin (compound C) C also suppresses GRP78 promoter activity induced by glucose withdrawal. Dorsomorphin (compound C) has no effect on 2DG-induced PERK activation and reduces the both basal and 2DG-induced AMPK phosphorylation levels in HT1080 cells
In Vivo
Dorsomorphin (10 mg/kg) reduces basal levels of hepcidin expression and increases serum iron concentrations in adult mice. Dorsomorphin (0.2 mg/kg, i.v.) significantly reduces VCAM-1 and ICAM-1 expression in the thoracic aorta of LPS-treated rats.
Animal model
Iron-replete mice
Formulation & Dosage
Dissolved in DMSO; 10 mg/kg; i.v. administration
References
Nat Chem Biol. 2008 Jan;4(1):33-41; Atherosclerosis. 2011 Nov;219(1):57-64. (3):302-15.
Purity ≥98%
COA